secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001437749-23-013899
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma Q3 revenue down 16% YoY; net income falls to $16K from $0.8M
--------------------------------------------------------------------------------

- Quarterly revenue $13.1M, down 16.2% from $15.6M in prior year.
- Operating income $44K vs $1.0M; net income $16K ($0.00 EPS) vs $0.8M ($0.03 EPS).
- Nine-month net loss $74K vs net income $2.3M in prior year.
- Two largest customers fell from 91% to 88% of revenue; overstocking during pandemic cited as cause.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774923013899/0001437749-23-013899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774923013899/inbp20230509_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-013899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer